N-hydroxy-4-methyl-1H-pyrrole-2-carboxamidine | 915229-90-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: N-hydroxy-4-methyl-1H-pyrrole-2-carboxamidine
• 英文别名: N'-hydroxy-4-methyl-1H-pyrrole-2-carboximidamide
• CAS: 915229-90-2
• 化学式: C₆H₉N₃O
• mdl: MFCD19215160
• 分子量: 139.157
• InChiKey: DNDJUBTUDCUEAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  74.4
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-hydroxy-4-methyl-1H-pyrrole-2-carboxamidine 在 N-羟基-7-氮杂苯并三氮唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.17h， 生成 (S)-3-[3-(4-methyl-1H-pyrrol-2-yl)-[1,2,4]oxadiazol-5-yl]-piperidine trifluoroacetate
  参考文献：
  名称：

  [EN] PHENYL-3-{(3-(1H-PYRROL-2-YL)-[1, 2 , 4]0XADIAZ0L-5-YL]PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  [FR] DERIVES DE PYRROLE UTILISES EN TANT QUE MODULATEURS ALLOSTERIQUES POSITIFS DES RECEPTEURS DE GLUTAMATE METABOTROPIQUE

  摘要：

  公开号：

  WO2006123257A3
• 作为产物：
  描述：

  4-甲基-2-吡咯甲酸 在 羟胺 、 N,N'-羰基二咪唑 、 三氯氧磷 作用下， 以 乙醇 、 水 、 乙腈 为溶剂， 反应 6.08h， 生成 N-hydroxy-4-methyl-1H-pyrrole-2-carboxamidine
  参考文献：
  名称：

  [EN] PHENYL-3-{(3-(1H-PYRROL-2-YL)-[1, 2 , 4]0XADIAZ0L-5-YL]PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  [FR] DERIVES DE PYRROLE UTILISES EN TANT QUE MODULATEURS ALLOSTERIQUES POSITIFS DES RECEPTEURS DE GLUTAMATE METABOTROPIQUE

  摘要：

  公开号：

  WO2006123257A3

文献信息

• TRICYCLIC MGLUR5 RECEPTOR MODULATORS
  申请人：Anthony Neville J.

  公开号：US20130210804A1

  公开（公告）日：2013-08-15

  The present invention is directed to tricyclic compounds which are positive allosteric modulators of metabotropic glutamate receptors, particularly the mGluR5 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及三环化合物，它们是代谢型谷氨酸受体的正向变构调节剂，特别是mGluR5受体，并且它们在治疗或预防与谷氨酸功能障碍相关的神经系统和精神障碍以及代谢型谷氨酸受体参与的疾病中具有用途。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗代谢型谷氨酸受体参与的疾病中的使用。
• Pyrrole Derivatives as Positive Allosteric Modulators of Metabotropic Receptors
  申请人：Gagliardi Stefania

  公开号：US20090203737A1

  公开（公告）日：2009-08-13

  The present invention relates to new compounds which are Pyrrole derivatives of formula (I) wherein A, B, P, Q 5 W, R 1 and R 2 are defined in the description. Invention compounds are useful in the prevention or treatment of central or peripheral nervous system disorders as well as other disorders modulated by mGluR5 receptors.

  本发明涉及新的化合物，它们是公式（I）的吡咯衍生物，其中A、B、P、Q5W、R1和R2在说明中有定义。发明化合物在预防或治疗中枢或外周神经系统疾病以及其他受mGluR5受体调节的疾病方面很有用。
• PHENYL-3-{(3-(1H-PYRROL-2-YL)-[1,2,4]OXADIAZOL-5-YL]PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：ADDEX Pharma S.A.

  公开号：EP1912979A2

  公开（公告）日：2008-04-23
• PHENYL-{3-(3-(1H-PYRROL-2-YL)-[1,2,4]OXADIAZOL-5-YL]PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：ADDEX Pharma S.A.

  公开号：EP1912979B1

  公开（公告）日：2011-06-22
• [EN] PYRROLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIS RECEPTORS<br/>[FR] DERIVES DE PYRROLE UTILISES EN TANT QUE MODULATEURS ALLOSTERIQUES POSITIFS DES RECEPTEURS DE GLUTAMATE METABOTROPIQUE
  申请人：ADDEX PHARMACEUTICALS SA

  公开号：WO2006123257A2

  公开（公告）日：2006-11-23

  (EN) The present invention provides new compounds of formula (I) as positive allosteric modulators of metabotropic receptors - subtype 5 ('mGluR5') which are useful for the treatment or prevention of central nervous system disorders such as for example, cognitive decline, both positive and negative symptoms in schizophrenia as well as other central or peripheral nervous system disorders in which the mGluR5 subtype of glutamate metabotropic receptor is involved. The invention is also directed to pharmaceutical compounds and compositions in the prevention or treatment of such diseases in which mGluR5 is involved. W represents (C4-C7)cycloalkyl, (C3-C7)heterocycloalkyl , (C3-C7)heterocycloalkyl-(C1-C3)alkyl or (C3-C7)heterocycloalkenyl ring; P represents a (C5-C7)heteroeycloalkyl, (C5-C7)heterocycloalkenyl ring or a heteroaryl group of formula (a), (b), (c), (d), (e), (f), (g), (h), (i). Q denotes a cycloalkyl, an aryl or heteroaryl group of formula (j), (k), (l), (m), (n). A is azo -N=N-, ethyl, ethenyl, ethynyl, -NR8C(=O)-, -NR8C(=O)-O-, -NR8C(=O)-NR9, NR8S(=O)2-, -C(=O)NR8-, -O-C(=O)NR8-, -S-, -S(=O)-, -S(=O)2-, -S(C=O)2NR8-, -C(=O)-O-, -O-C(=O)-, -C(=NR8)NR9-, C(C=NOR8)NR9- , -NR8C(=NOR9)-, =N-O-, -O-N=CH- or a group aryl or heteroaryl of formula, (o), (p), (q), (r), (s), (t), (u), (v), (w), (x). The other substituents are defined in the claims.(FR) L'invention concerne de nouveaux composés qui sont des dérivés de pyrrole de formule (I) dans laquelle A, B, P, Q, W, R1 et R2 sont tels que définis dans la description. Les composés selon l'invention sont utiles dans la prévention ou le traitement des troubles du système nerveux central ou périphérique, et d'autres troubles modulés par les récepteurs mGluR5.